Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses.

Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.

The present invention provides a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, a method for radiolabeling a hexa-lactoside positron emission tomography (PET) imaging agent for a liver receptor with Ga-68, and a hexa-lactoside PET imaging agent for a liver receptor. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA obtained by conjugating hexa-lactoside to a chelating agent p-thiocyanate-benzyl-triazanonane diacetic acid-glutamic acid in the presence of triethyl amine/dimethyl formamide as a solvent. The radiolabeling method comprises labeling with Ga-68 at room temperature. According to the present invention, the labeling effect is stable, the labeling efficiency of the labeled product is greater than 95%, the labeled product is highly stable and the radiochemical purity is still greater than 90% after 4 hours.

Methods for reverse automated nucleic acid synthesis, and 5-H-phosphonates suitable for use in the same, as well as methods for making 5-H-phosphonates, are described.

Embodiments of the present application relate to the preparation of 2-O-protected nucleoside phosphoramidites and conjugation of the 2-O-protected nucleoside to a solid support. More specifically, the present application relates to nucleosides having a hydroxy protecting group at the 2 position that reduces migration to the 3 position during RNA (e.g., mRNA) synthesis and can be readily removed under mild conditions without the use of toxic metal-containing reagents. Methods of using the nucleosides described herein in RNA synthesis are also disclosed.

The present invention relates to a process for the purification of methylcobalamin, namely from iron cyanide impurities, comprising contacting a solution comprising methylcobalamin and iron cyanide anions with a strongly basic anion exchange resin. This purification process can advantageously be used for removing iron cyanide impurities from methylcobalamin obtained by reductive methylation of cyanocobalamin and wherein iron (II) salts are used as cyanide scavengers, thus providing methylcobalamin with a reduced iron content. Methylcobalamin (R is methyl). ##STR00001##

The present invention relates to a process for the purification of methylcobalamin, namely from iron cyanide impurities, comprising contacting a solution comprising methylcobalamin and iron cyanide anions with a strongly basic anion exchange resin. This purification process can advantageously be used for removing iron cyanide impurities from methylcobalamin obtained by reductive methylation of cyanocobalamin and wherein iron (II) salts are used as cyanide scavengers, thus providing methylcobalamin with a reduced iron content. Methylcobalamin (R is methyl). ##STR00001##

The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.

The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.